



FIG. 1



Dose-Dependent Increase in Peak Flow Velocity Caused by CVT-3146



CVT-3146 and Coronary Flow Velocity
Duration of Effect:

Duration ≥2.5 Baseline	
Dose (n)	Mean ± SEM
10 µg (4)	0
30 µg (4)	0
100 µg (3)	0.2 ± 0.2 minutes
300 µg (4)	2.2 ± 1.3 minutes
400 µg (8)	2.8 ± 0.8 minutes
500 µg (4)	2.9 ± 1.3 minutes

Figure 3

4/17

Time Course of APV Ratio (CVT-3146 400 µg)





Figure 4

5/17



6/17




Figure 6

7/17


All Drug-Related Adverse Events Were Mild and Transient

Adverse Event	All Doses 400 µg	
	(n = 36)	(n = 9)
chest discomfort	3	3
increased heart rate	3	1
hypotension	2	2
flushing	2	1
shortness of breath	2	0
funny taste in mouth	1	0
sensation in mouth, sinus, and chest	1	0
headache	1	0
tingling in hands	1	1
heart racing	1	1
bradycardia	1	1
lightheadedness	1	1
cough	1	0
nausea and vomiting	1	0

Figure 7


8/17

Figure 8
Mean CVT-3146 Plasma Concentration in
Healthy Male Volunteers - Supine Position




9/17

Figure 9




10/17

Figure 10



11/17

Figure 11



12/17

Figure 12




Figure 13




Figure 14





Figure 15






Figure 16




Figure 17




Figure 18